Owkin Stock
AI Medical Research Testing
Sign up today and learn more about Owkin Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Owkin Stock
Owkin is a startup that provides machine learning that allows medical researchers to test AI models on distributed data. The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board. It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York.
Investors
Funding History
October 2016 | $2.1M |
---|---|
January 2018 | $11.0M |
May 2018 | $5.0M |
March 2019 | $13.0M |
May 2020 | $25.0M |
July 2020 | $18.0M |
Management
Chief Executive Officer
Thomas Clozel
Press
pharmaphorum - Mar, 27 2024
Ex-BioMarin CEO Bienaimé re-emerges at Owkinbusinesswire - Mar, 25 2024
Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkinendpts - Feb, 25 2024
Owkin launches new startup to âcapture laws of biologyâ with $35M seed roundbusinesswire - Feb, 22 2024
Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biologypymnts - Feb, 20 2024
TechBio Firm Owkin and AWS Team on GenAI and Drug Discovery